These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 32572786)

  • 61. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
    Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
    Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer.
    Wang SR; Malik S; Tan IB; Chan YS; Hoi Q; Ow JL; He CZ; Ching CE; Poh DYS; Seah HM; Cheung KHT; Perumal D; Devasia AG; Pan L; Ang S; Lee SE; Ten R; Chua C; Tan DSW; Qu JZZ; Bylstra YM; Lim L; Lezhava A; Ng PC; Wong CW; Lim T; Tan P
    J Mol Diagn; 2016 May; 18(3):416-424. PubMed ID: 26970585
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.
    Park K; Tran H; Eng KW; Ramazanoglu S; Marrero Rolon RM; Scognamiglio T; Borczuk A; Mosquera JM; Pan Q; Sboner A; Rubin MA; Elemento O; Rennert H; Fernandes H; Song W
    Arch Pathol Lab Med; 2020 Dec; 144(12):1535-1546. PubMed ID: 32045275
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies.
    Goodman AM; Choi M; Wieduwilt M; Mulroney C; Costello C; Frampton G; Miller V; Kurzrock R
    JCO Precis Oncol; 2017 Jun; 1():. PubMed ID: 28681041
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
    Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
    BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.
    Balendran S; Liebmann-Reindl S; Berghoff AS; Reischer T; Popitsch N; Geier CB; Kenner L; Birner P; Streubel B; Preusser M
    J Neurooncol; 2017 Jul; 133(3):469-476. PubMed ID: 28497333
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prevalence of pathogenic variants in actionable genes in advanced ovarian cancer: a next-generation sequencing analysis of a nationwide registry study.
    Kang S; Yu YL; Cho SY; Park SY
    Eur J Cancer; 2020 Dec; 141():185-192. PubMed ID: 33166861
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
    Hamblin A; Wordsworth S; Fermont JM; Page S; Kaur K; Camps C; Kaisaki P; Gupta A; Talbot D; Middleton M; Henderson S; Cutts A; Vavoulis DV; Housby N; Tomlinson I; Taylor JC; Schuh A
    PLoS Med; 2017 Feb; 14(2):e1002230. PubMed ID: 28196074
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical next-generation sequencing in patients with non-small cell lung cancer.
    Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
    Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
    Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
    BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
    Mosele F; Remon J; Mateo J; Westphalen CB; Barlesi F; Lolkema MP; Normanno N; Scarpa A; Robson M; Meric-Bernstam F; Wagle N; Stenzinger A; Bonastre J; Bayle A; Michiels S; Bièche I; Rouleau E; Jezdic S; Douillard JY; Reis-Filho JS; Dienstmann R; André F
    Ann Oncol; 2020 Nov; 31(11):1491-1505. PubMed ID: 32853681
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Author Correction: Pan-cancer image-based detection of clinically actionable genetic alterations.
    Kather JN; Heij LR; Grabsch HI; Loeffler C; Echle A; Muti HS; Krause J; Niehues JM; Sommer KAJ; Bankhead P; Kooreman LFS; Schulte JJ; Cipriani NA; Buelow RD; Boor P; Ortiz-Brüchle N; Hanby AM; Speirs V; Kochanny S; Patnaik A; Srisuwananukorn A; Brenner H; Hoffmeister M; van den Brandt PA; Jäger D; Trautwein C; Pearson AT; Luedde T
    Nat Cancer; 2020 Nov; 1(11):1129. PubMed ID: 35122072
    [No Abstract]   [Full Text] [Related]  

  • 73. Major driver mutations are shared between sinonasal intestinal-type adenocarcinoma and the morphologically identical colorectal adenocarcinoma.
    Sjöstedt S; Schmidt AY; Vieira FG; Willemoe GL; Agander TK; Olsen C; Nielsen FC; von Buchwald C
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1019-1027. PubMed ID: 33051725
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing.
    Hyung S; Han B; Jung J; Kim ST; Hong JY; Park SH; Zang DY; Park JO; Park YS; Kim KM; Kang WK; Lee J
    J Oncol; 2022; 2022():9714570. PubMed ID: 35342406
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
    Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
    J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.
    Beg S; Bareja R; Ohara K; Eng KW; Wilkes DC; Pisapia DJ; Zoughbi WA; Kudman S; Zhang W; Rao R; Manohar J; Kane T; Sigouros M; Xiang JZ; Khani F; Robinson BD; Faltas BM; Sternberg CN; Sboner A; Beltran H; Elemento O; Mosquera JM
    Transl Oncol; 2021 Jan; 14(1):100944. PubMed ID: 33190043
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Correction: Exome sequencing of Pakistani consanguineous families identifies 30 novel candidate genes for recessive intellectual disability.
    Riazuddin S; Hussain M; Razzaq A; Iqbal Z; Shahzad M; Polla DL; Song Y; van Beusekom E; Khan AA; Tomas-Roca L; Rashid M; Zahoor MY; Wissink-Lindhout WM; Basra MAR; Ansar M; Agha Z; van Heeswijk K; Rasheed F; Van de Vorst M; Veltman JA; Gilissen C; Akram J; Kleefstra T; Assir MZ; ; Grozeva D; Carss K; Raymond FL; O'Connor TD; Riazuddin SA; Khan SN; Ahmed ZM; de Brouwer APM; van Bokhoven H; Riazuddin S
    Mol Psychiatry; 2020 Nov; 25(11):3101-3102. PubMed ID: 30171209
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.
    Morganti S; Tarantino P; Ferraro E; D'Amico P; Duso BA; Curigliano G
    Adv Exp Med Biol; 2019; 1168():9-30. PubMed ID: 31713162
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Correction to: Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.
    Pestinger V; Smith M; Sillo T; Findlay JM; Laes JF; Martin G; Middleton G; Taniere P; Beggs AD
    Mol Diagn Ther; 2020 Aug; 24(4):505. PubMed ID: 32572786
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.